Protective effect of a DNA vaccine delivered in attenuated Salmonella typhimurium against Toxoplasma gondii infection in mice

Qu, Daofeng; Wang, Suhua; Cai, Weiming; Du, Aifang

doi:10.1016/j.vaccine.2008.06.030

Cited by 38 publications

(27 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Very interesting studies by Cong et al [29] and Qu et al [65] showed that a DNA vaccine delivered in attenuated Salmonella typhimurium, containing SAG1 DNA, can elicit a specific immune response as well as provide effective protection against T. gondii infection (Table 4). …”

Section: Reviewmentioning

confidence: 99%

“…Mice (CBA/J) immunized with plasmid DNA encoding the immature form of the MIC3 protein displayed significant protection against oral challenge with T. gondii 76K cysts, exhibiting fewer brain cysts than the control mice [82]. Mice orally immunized with ZJ111/pCDNA3-SAG1 significantly increased survival rate after challenge with 500 tachyzoites of highly virulent RH strain Cellular immune response was elicited with production of IFN-g [65] SAG: Surface antigen. …”

Section: Microneme Antigens As Vaccine Candidatesmentioning

confidence: 99%

See 1 more Smart Citation

Current status of toxoplasmosis vaccine development

Kur¹,

Holec-Gąsior²,

Hiszczyńska-Sawicka³

2009

Expert Review of Vaccines

123

View full text Add to dashboard Cite

Toxoplasmosis, caused by an intracellular protozoan parasite, Toxoplasma gondii, is widespread throughout the world. The disease is of major medical and veterinary importance, being a cause of congenital disease and abortion in humans and domestic animals. In addition, recently it has gained importance owing to toxoplasma encephalitis in AIDS patients. In the last few years, there has been considerable progress towards the development of a vaccine for toxoplasmosis, and a vaccine based on the live-attenuated S48 strain was developed for veterinary uses. However, this vaccine is expensive, causes side effects and has a short shelf life. Furthermore, this vaccine may revert to a pathogenic strain and, therefore, is not suitable for human use. Various experimental studies have shown that it may be possible to develop a vaccine against human toxoplasmosis. Recent progress in knowledge of the protective immune response generated by T. gondii and the current status of development of a vaccine for toxoplasmosis are highlighted.

show abstract

Section: Reviewmentioning

confidence: 99%

Section: Microneme Antigens As Vaccine Candidatesmentioning

confidence: 99%

Current status of toxoplasmosis vaccine development

Kur¹,

Holec-Gąsior²,

Hiszczyńska-Sawicka³

2009

Expert Review of Vaccines

123

View full text Add to dashboard Cite

show abstract

“…It has been clearly established that the use of attenuated Salmonella strains as live oral vaccines is a safe and effective means of inducing significant humoral and secretory antibody responses in animal species, including humans and mice (8,16,21,(32)(33)(34). The use of plasmid-based expression systems to elevate foreign antigen levels in Salmonella live vaccine vectors is ideal, but these systems have the serious disadvantages of instability and selective requirements in vivo (10,14,17,38).…”

mentioning

confidence: 99%

Oral Vaccination with AttenuatedSalmonella entericaStrains Encoding T-Cell Epitopes from Tumor Antigen NY-ESO-1 Induces Specific Cytotoxic T-Lymphocyte Responses

Meng

Dong

Huang

et al. 2010

Clin Vaccine Immunol

View full text Add to dashboard Cite

Bacterial fimbriae can accept foreign peptides and display them on the cell surface. A highly efficient gene replacement method was used to generate peptide vaccines based on Salmonella enterica serovar Typhimurium SL3261. The T-cell epitopes (NY-ESO-1 p157-165 and p157-167) from NY-ESO-1, which is a promising target antigen in patients for the specific immune recognition of cancer, were incorporated into the gene encoding AgfA (the major subunit protein of thin aggregative fimbriae of Salmonella) by replacing an equal length of the DNA segment. To improve cytotoxic T-lymphocyte recognition, both termini of the peptide were flanked by double alanine (AA) residues. Immunofluorescence microscopy with AgfA-specific antiserum verified the expression of chimeric AgfA, which was also proved by a Congo red binding assay. Modulating the immune system to control cancer has been a challenge for cancer immunotherapists for many years. A number of clinical trials have indeed demonstrated that objective tumor regressions can occur in the setting of cancer vaccinations (1,19,31

show abstract

“…Delivery of a SAG1-SAG2 fusion protein linked to cholera toxin A 2 /B via an attenuated Salmonella typhimurium strain afforded 40% survival in BALB/c mice after challenge with the T. gondii RH isolate, compared with 100% mortality in the SAG1-2 immunized group (Cong et al 2005). Recently, 10% and 20% survival was obtained with an attenuated S. typhimurium strain delivering a SAG1 DNA vaccine in ICR mice, while all naïve mice succumbed to infection (Qu et al 2008).…”

Section: Live Attenuated Vectorsmentioning

confidence: 99%